IL136592A - (E)-3-[1-N-n-BUTYL-5-[2-(2-CARBOXYPHENYL) METHOXY-4-CHLOROPHENYL]-1H-PYRAZOL-4-YL]-2-[(5-METHOXY-2,3-DIHYDROBENZOFURAN-6- YL) METHYL]-PROP-2-ENOIC ACID MONOARGININYL SALT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF - Google Patents

(E)-3-[1-N-n-BUTYL-5-[2-(2-CARBOXYPHENYL) METHOXY-4-CHLOROPHENYL]-1H-PYRAZOL-4-YL]-2-[(5-METHOXY-2,3-DIHYDROBENZOFURAN-6- YL) METHYL]-PROP-2-ENOIC ACID MONOARGININYL SALT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF

Info

Publication number
IL136592A
IL136592A IL13659298A IL13659298A IL136592A IL 136592 A IL136592 A IL 136592A IL 13659298 A IL13659298 A IL 13659298A IL 13659298 A IL13659298 A IL 13659298A IL 136592 A IL136592 A IL 136592A
Authority
IL
Israel
Prior art keywords
methoxy
dihydrobenzofuran
carboxyphenyl
pyrazol
chlorophenyl
Prior art date
Application number
IL13659298A
Other languages
English (en)
Other versions
IL136592A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL136592A0 publication Critical patent/IL136592A0/xx
Publication of IL136592A publication Critical patent/IL136592A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13659298A 1997-12-08 1998-12-07 (E)-3-[1-N-n-BUTYL-5-[2-(2-CARBOXYPHENYL) METHOXY-4-CHLOROPHENYL]-1H-PYRAZOL-4-YL]-2-[(5-METHOXY-2,3-DIHYDROBENZOFURAN-6- YL) METHYL]-PROP-2-ENOIC ACID MONOARGININYL SALT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF IL136592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6773297P 1997-12-08 1997-12-08
PCT/US1998/025903 WO1999029685A1 (en) 1997-12-08 1998-12-07 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2-[(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt

Publications (2)

Publication Number Publication Date
IL136592A0 IL136592A0 (en) 2001-06-14
IL136592A true IL136592A (en) 2003-03-12

Family

ID=22078027

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13659298A IL136592A (en) 1997-12-08 1998-12-07 (E)-3-[1-N-n-BUTYL-5-[2-(2-CARBOXYPHENYL) METHOXY-4-CHLOROPHENYL]-1H-PYRAZOL-4-YL]-2-[(5-METHOXY-2,3-DIHYDROBENZOFURAN-6- YL) METHYL]-PROP-2-ENOIC ACID MONOARGININYL SALT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF

Country Status (24)

Country Link
US (1) US6300359B1 (de)
EP (1) EP1037888B1 (de)
JP (1) JP2001525405A (de)
KR (1) KR20010040292A (de)
CN (1) CN1281447A (de)
AR (1) AR017426A1 (de)
AT (1) ATE223404T1 (de)
AU (1) AU747108B2 (de)
BR (1) BR9813409A (de)
CA (1) CA2312965A1 (de)
CO (1) CO5021171A1 (de)
DE (1) DE69807745T2 (de)
DK (1) DK1037888T3 (de)
ES (1) ES2182383T3 (de)
HU (1) HUP0100423A3 (de)
IL (1) IL136592A (de)
NO (1) NO20002904L (de)
NZ (1) NZ504898A (de)
PL (1) PL341601A1 (de)
PT (1) PT1037888E (de)
TR (1) TR200001633T2 (de)
TW (1) TW505643B (de)
WO (1) WO1999029685A1 (de)
ZA (1) ZA9811154B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007067779A2 (en) * 2005-12-08 2007-06-14 Tsrl, Inc. Methods and compositions for drug delivery enhancement
CN103536923A (zh) * 2007-11-05 2014-01-29 阿拉维制药公司 用于口服给药极性药剂的提高生物利用度的制剂
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
EP3579914A4 (de) 2017-03-09 2020-11-25 Nevro Corp. Kontaktelektroden und abgabewerkzeuge und zugehörige systeme und verfahren
EP3758793A4 (de) 2018-03-29 2021-12-08 Nevro Corp. Leitungen mit seitenwandöffnungen sowie zugehörige systeme und verfahren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
WO1997004772A1 (en) * 1995-08-02 1997-02-13 Smithkline Beecham Corporation Endothelin receptor antagonists

Also Published As

Publication number Publication date
DE69807745D1 (de) 2002-10-10
AU747108B2 (en) 2002-05-09
PL341601A1 (en) 2001-04-23
CN1281447A (zh) 2001-01-24
HUP0100423A2 (hu) 2002-05-29
DK1037888T3 (da) 2003-01-06
NO20002904D0 (no) 2000-06-07
CA2312965A1 (en) 1999-06-17
US6300359B1 (en) 2001-10-09
HUP0100423A3 (en) 2002-08-28
JP2001525405A (ja) 2001-12-11
AU1713899A (en) 1999-06-28
WO1999029685A1 (en) 1999-06-17
EP1037888A4 (de) 2001-08-22
DE69807745T2 (de) 2003-05-15
ES2182383T3 (es) 2003-03-01
NO20002904L (no) 2000-06-07
KR20010040292A (ko) 2001-05-15
EP1037888B1 (de) 2002-09-04
BR9813409A (pt) 2000-10-10
TR200001633T2 (tr) 2001-07-23
AR017426A1 (es) 2001-09-05
HK1032229A1 (en) 2001-07-13
PT1037888E (pt) 2002-12-31
CO5021171A1 (es) 2001-03-27
ATE223404T1 (de) 2002-09-15
IL136592A0 (en) 2001-06-14
ZA9811154B (en) 1999-06-08
TW505643B (en) 2002-10-11
EP1037888A1 (de) 2000-09-27
NZ504898A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
FR13C0010I2 (fr) Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci
IL160714A0 (en) Heterocyclic substituted 2-(4-phenoxy) pyridine derivatives and pharmaceutical compositions containing the same
DE60038481D1 (de) Kristalline form des (r)-2-äää3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinylümethylüsulfinylü-1h-benzimidazols
HUP0201311A3 (en) 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7)receptor agonists, method for the production and the use thereof and pharmaceutical preparations containing said compounds
IL149420A0 (en) Heterocyclic substituted pyrazolones
ZA98363B (en) 4-(3-heterocyclyl-1-benzoyl) pyrazoles.
MX9906600A (es) 4-(3-heterociclil-1-benzoil)pirazoles
EP1147107A4 (de) Angiogeneseinhibitoren
DZ3001A1 (fr) Sel de potassium d'oméprazole-(S).
FR2791059B1 (fr) Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee
PT1171437E (pt) Pesticidas derivados de indazole ou benzotriazole
PL351527A1 (en) Substituted benzoylpyrazoles as herbicides
HUP0100423A3 (en) (e)-3-[1-n-butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1h-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt, process for its preparation and pharmaceutical use
HUP9900344A3 (en) Process for the preparation of an optically active indoline-2-carboxylic acid or derivative thereof
DE50003732D1 (de) 4-(3',4'-heterocyclylbenzoyl)pyrazole als herbizide
NO995619D0 (no) Kjemisk fremgangsmåte for fremstilling av 1-substituerte 3-hydroksymetyl-4-(4-fluorfenyl)tetrahydropyridiner
HUP0104797A3 (en) Method for preparing 4-(3-pyridinyl)-1h-imidazole and the intermediates used
SI1037888T1 (en) (e)-3-(1-n-butyl- 5-(2-(2-carboxyphenyl)methoxy- 4-chlorophenyl)-1h- pyrazol-4-yl)-2- ((5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl)- prop-2-enoic acid monoargininyl salt
IL132340A0 (en) Substituted 4-(3-alkenyl-benzoyl) pyrazoles
FR2769820B1 (fr) Jardiniere pour balcon
SI1192134T1 (sl) Postopki za pripravo (R)-alfa-(2,3-dimetoksifenil)-1-2-(4-fluorofenil) etil)-4-piperidinmetanola
IT1313578B1 (it) Metodo per l'essicamento di acido borico.
AU6142800A (en) Pre-emergence herbicide formed from animal protein
ZA987925B (en) 2-(Arylphenyl)amino-imidazoline derivatives
FR2793650B1 (fr) Dispositif d'identification pour animaux

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees